• Je něco špatně v tomto záznamu ?

CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials

K. Khalaf, K. Janowicz, M. Dyszkiewicz-Konwińska, G. Hutchings, C. Dompe, L. Moncrieff, M. Jankowski, M. Machnik, U. Oleksiewicz, I. Kocherova, J. Petitte, P. Mozdziak, JA. Shibli, D. Iżycki, M. Józkowiak, H. Piotrowska-Kempisty, MT. Skowroński,...

. 2020 ; 11 (8) : . [pub] 20200811

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, Research Support, U.S. Gov't, Non-P.H.S., přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012273

Even though chemotherapy and immunotherapy emerged to limit continual and unregulated proliferation of cancer cells, currently available therapeutic agents are associated with high toxicity levels and low success rates. Additionally, ongoing multi-targeted therapies are limited only for few carcinogenesis pathways, due to continually emerging and evolving mutations of proto-oncogenes and tumor-suppressive genes. CRISPR/Cas9, as a specific gene-editing tool, is used to correct causative mutations with minimal toxicity, but is also employed as an adjuvant to immunotherapy to achieve a more robust immunological response. Some of the most critical limitations of the CRISPR/Cas9 technology include off-target mutations, resulting in nonspecific restrictions of DNA upstream of the Protospacer Adjacent Motifs (PAM), ethical agreements, and the lack of a scientific consensus aiming at risk evaluation. Currently, CRISPR/Cas9 is tested on animal models to enhance genome editing specificity and induce a stronger anti-tumor response. Moreover, ongoing clinical trials use the CRISPR/Cas9 system in immune cells to modify genomes in a target-specific manner. Recently, error-free in vitro systems have been engineered to overcome limitations of this gene-editing system. The aim of the article is to present the knowledge concerning the use of CRISPR Cas9 technique in targeting treatment-resistant cancers. Additionally, the use of CRISPR/Cas9 is aided as an emerging supplementation of immunotherapy, currently used in experimental oncology. Demonstrating further, applications and advances of the CRISPR/Cas9 technique are presented in animal models and human clinical trials. Concluding, an overview of the limitations of the gene-editing tool is proffered.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012273
003      
CZ-PrNML
005      
20210713113109.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/genes11080921 $2 doi
035    __
$a (PubMed)32796761
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Khalaf, Khalil $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland
245    10
$a CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials / $c K. Khalaf, K. Janowicz, M. Dyszkiewicz-Konwińska, G. Hutchings, C. Dompe, L. Moncrieff, M. Jankowski, M. Machnik, U. Oleksiewicz, I. Kocherova, J. Petitte, P. Mozdziak, JA. Shibli, D. Iżycki, M. Józkowiak, H. Piotrowska-Kempisty, MT. Skowroński, P. Antosik, B. Kempisty
520    9_
$a Even though chemotherapy and immunotherapy emerged to limit continual and unregulated proliferation of cancer cells, currently available therapeutic agents are associated with high toxicity levels and low success rates. Additionally, ongoing multi-targeted therapies are limited only for few carcinogenesis pathways, due to continually emerging and evolving mutations of proto-oncogenes and tumor-suppressive genes. CRISPR/Cas9, as a specific gene-editing tool, is used to correct causative mutations with minimal toxicity, but is also employed as an adjuvant to immunotherapy to achieve a more robust immunological response. Some of the most critical limitations of the CRISPR/Cas9 technology include off-target mutations, resulting in nonspecific restrictions of DNA upstream of the Protospacer Adjacent Motifs (PAM), ethical agreements, and the lack of a scientific consensus aiming at risk evaluation. Currently, CRISPR/Cas9 is tested on animal models to enhance genome editing specificity and induce a stronger anti-tumor response. Moreover, ongoing clinical trials use the CRISPR/Cas9 system in immune cells to modify genomes in a target-specific manner. Recently, error-free in vitro systems have been engineered to overcome limitations of this gene-editing system. The aim of the article is to present the knowledge concerning the use of CRISPR Cas9 technique in targeting treatment-resistant cancers. Additionally, the use of CRISPR/Cas9 is aided as an emerging supplementation of immunotherapy, currently used in experimental oncology. Demonstrating further, applications and advances of the CRISPR/Cas9 technique are presented in animal models and human clinical trials. Concluding, an overview of the limitations of the gene-editing tool is proffered.
650    _2
$a zvířata $7 D000818
650    12
$a CRISPR-Cas systémy $7 D064113
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a nemoc $7 D004194
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    12
$a editace genu $7 D000072669
650    12
$a genetická terapie $7 D015316
650    _2
$a lidé $7 D006801
650    12
$a imunoterapie $7 D007167
650    _2
$a imunoterapie adoptivní $7 D016219
650    _2
$a nádory $x etiologie $x terapie $7 D009369
650    _2
$a individualizovaná medicína $x metody $7 D057285
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a přehledy $7 D016454
700    1_
$a Janowicz, Krzysztof $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland ; The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK
700    1_
$a Dyszkiewicz-Konwińska, Marta $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland ; Department of Biomaterials and Experimental Dentistry, Poznan University of Medical Sciences, 60-812 Poznań, Poland
700    1_
$a Hutchings, Greg $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland ; The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK
700    1_
$a Dompe, Claudia $u The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK ; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland
700    1_
$a Moncrieff, Lisa $u The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK ; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland
700    1_
$a Jankowski, Maurycy $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland
700    1_
$a Machnik, Marta $u Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408 Poznan, Poland ; Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland
700    1_
$a Oleksiewicz, Urszula $u Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408 Poznan, Poland ; Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland
700    1_
$a Kocherova, Ievgeniia $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland
700    1_
$a Petitte, Jim $u Prestage Department of Poultry Science, North Carolina State University, Raleigh, NC 27695, USA
700    1_
$a Mozdziak, Paul $u Physiology Graduate Program, North Carolina State University, Raleigh, NC 27695, USA
700    1_
$a Shibli, Jamil A $u Department of Periodontology and Oral Implantology, Dental Research Division, University of Guarulhos, Guarulhos 07023-070, Brazil
700    1_
$a Iżycki, Dariusz $u Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408 Poznan, Poland
700    1_
$a Józkowiak, Małgorzata $u Department of Toxicology, Poznan University of Medical Sciences, 61-631 Poznań, Poland
700    1_
$a Piotrowska-Kempisty, Hanna $u Department of Toxicology, Poznan University of Medical Sciences, 61-631 Poznań, Poland
700    1_
$a Skowroński, Mariusz T $u Department of Basic and Preclinical Sciences, Institute of Veterinary Medicine, Nicolaus Copernicus University in Torun, 87-100 Toruń, Poland
700    1_
$a Antosik, Paweł $u Department of Veterinary Surgery, Nicolaus Copernicus University in Torun, 87-100 Toruń, Poland
700    1_
$a Kempisty, Bartosz $u Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznań, Poland ; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland ; Department of Veterinary Surgery, Nicolaus Copernicus University in Torun, 87-100 Toruń, Poland $u Department of Obstetrics and Gynecology, University Hospital and Masaryk University, 601 77 Brno, Czech Republic
773    0_
$w MED00174652 $t Genes $x 2073-4425 $g Roč. 11, č. 8 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32796761 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210713113106 $b ABA008
999    __
$a ok $b bmc $g 1650608 $s 1132652
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c 8 $e 20200811 $i 2073-4425 $m Genes $n Genes $x MED00174652
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace